{"id":240092,"date":"2025-12-26T11:23:17","date_gmt":"2025-12-26T11:23:17","guid":{"rendered":"https:\/\/evertise.net\/?p=129881"},"modified":"2025-12-26T11:23:17","modified_gmt":"2025-12-26T11:23:17","slug":"deep-intelligent-pharma-dip-raises-nearly-50-million-usd-in-series-d-financing","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2025\/12\/26\/deep-intelligent-pharma-dip-raises-nearly-50-million-usd-in-series-d-financing\/","title":{"rendered":"Deep Intelligent Pharma (DIP) Raises Nearly 50 Million USD in Series D Financing"},"content":{"rendered":"

The Singapore-based AI clinical trial engine powering Asia\u2019s\u2014especially China\u2019s\u2014rapid rise in the biotech industry.<\/span><\/i><\/p>\n

Deep Intelligent Pharma (DIP)<\/span><\/a>, a global leader in AI-driven drug R&D platforms, announced the completion of nearly US$50 million in Series D financing. The round was led by CDH Baifu, with continued participation from existing investors Xinding Capital and HongShan Capital. Index Capital served as the exclusive financial advisor.<\/span>
\n<\/span>The new funds will primarily support iterative development of DIP\u2019s end-to-end autonomous clinical system and the expansion of its global commercialization network, accelerating a generational leap from \u201cassistive tools\u201d to \u201cdecision-making infrastructure.\u201d<\/span><\/p>\n

Asia\u2019s biotech industry\u2014especially China\u2019s\u2014is undergoing what many are calling a \u201cDeepSeek moment,\u201d developing drugs at unprecedented speed and scale. DIP, the Singapore-based company whose AI technology significantly lowers clinical trial costs, accelerates development timelines, and increases success rates, has become one of <\/span>key engines behind China\u2019s biotech rise<\/span><\/a>.<\/span><\/p>\n

\"\"<\/p>\n

1. Defining the Pharmaceutical Industry\u2019s \u201cAI Brain\u201d: Upgrading from \u201cEfficiency Gains\u201d to \u201cAsset Success Probability\u201d<\/b><\/p>\n

Traditional drug R&D faces a \u201cdual dilemma\u201d: long development cycles and high costs, with nearly 40% of failures attributable to flaws in clinical trial design or unscientific factors in execution. The industry no longer needs simple \u201coutsourced manpower,\u201d but rather \u201cintelligent decision systems\u201d that can precisely avoid risks.<\/span><\/p>\n

DIP breaks away from the traditional CRO model of \u201cscaling manpower\u201d and redefines the value anchor of AI in drug development\u2014not just doing things <\/span>faster<\/span><\/i>, but doing them <\/span>right<\/span><\/i>.<\/span><\/p>\n

\u201cWe don\u2019t define success as merely \u2018finishing\u2019 a task, but truly \u2018accomplishing\u2019 it,\u201d said Li Xing, Founder and CEO of DIP. \u201cThrough AI intervention, we simulate a full-dimension \u2018commercial endpoint\u2019 analysis in early clinical stages, eliminating execution noise and design flaws. Our goal is to elevate drug asset success rates to their theoretical maximum.\u201d<\/span><\/p>\n

2. Building Strong Technological Barriers: A Tens-of-Thousands-Scale Agent Cluster Based on \u201cCognitive Atomism\u201d and \u201cHuman Bionics\u201d<\/b><\/p>\n

After years of research and development, DIP has created the industry\u2019s first \u201chuman-brain-like multi-agent ecosystem\u201d (Synaptic Agent Ecosystem) based on bionics. It features three defining characteristics and advantages:<\/span><\/p>\n